Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib Dose Escalation in HER2+ Advanced Breast Cancer
NCT06254690Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jan 2024
- Primary completion
- Nov 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pyrotinib in breast cancer, sponsored by Jiangsu Provincial People's Hospital. Started Jan 2024; status: recruiting.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06254690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06254690.